(+)-JQ-1
中文名稱:(+)-JQ-1
英文名稱:(+)-JQ-1
產(chǎn)品規(guī)格:1mL(10mM)|2mg|5mg|10mg|50mg|100mg|200mg|500m
(+)-JQ-1是一種BET bromodomain抑制劑,抑制BRD4(1)和BRD4(2)的IC50分別為77 nM和33 nM。(+)-JQ-1激活自噬。在DMSO中的溶解度≥ 45 mg/mL (98.47 mM)。
注:本品僅可用于科研實(shí)驗(yàn),嚴(yán)禁用于臨床醫(yī)療及其他用途!
CAS號(hào):1268524-70-4
別名:JQ1
純度:99.90%
分子式:C23H25ClN4O2S
分子量:456.99
結(jié)構(gòu)式:
保存條件:4℃,有效期2年。溶入溶劑后-20℃請(qǐng)盡量在一個(gè)月內(nèi)使用。
體外研究
(+)-JQ-1 represents a potent, highly specific and Kac competitive inhibitor for the BET family of bromodomains. (+)-JQ-1 (100 nM, 48 h) prompts squamous differentiation exhibited by cell spindling, flattening and increased expression of keratin. (+)-JQ-1 (250 nM) induces rapid expression of keratin in treated NMC 797 cells compared to (-)-JQ1 (250 nM) and vehicle controls, as determined by quantitative immunohistochemistry.(+)-JQ-1 (250 nM) elicits a time-dependent induction of strong (3+) keratin staining of treated NMC 797 cells, compared to (-)-JQ1 (250 nM). De-repression of autophagy genes is observed almost immediately after (+)-JQ-1 addition. (+)-JQ-1 is a potent thienodiazepine inhibitor (Kd=90 nM) of the BET family coactivator protein BRD4, which is implicated in the pathogenesis of cancer via transcriptional control of the MYC oncogene. Dose-ranging studies of (+)-JQ-1 demonstrates potent inhibition of H4Kac4 binding with a IC50 value of 10 nM for murine BRDT(1) and 11 nM for human BRDT(1).
貯存液制備(溶劑為DMSO):
1mM
2.1882mL
10.9412mL
21.8823mL
5mM
0.4376mL
2.1882mL
4.3765mL
10mM
0.2188mL
1.0941mL
2.1882mL
體內(nèi)研究
Matched cohorts of mice with established tumors are randomized to treatment with (+)-JQ1 (50 mg/kg) or vehicle, administered by daily intraperitoneal injection. Prior to randomization, and after four days of therapy, mice are evaluated by FDG-PET imaging. A marked reduction in FDG uptake is observed with (+)-JQ1 treatment. Tumor-volume measurements confirm a reduction in tumor growth with JQ1 treatment. Pharmacokinetic studies of (+)-JQ1 are performed in CD1 mice following intravenous and oral administration. Mean plasma concentration-time profiles of (+)-JQ1 after intravenous dosing (5 mg/kg). The pharmacokinetic parameters for intravenous (+)-JQ1 demonstrate excellent drug exposure (AUC=2090 hr*ng/mL) and an approximately one hour half-life (T1/2). Mean plasma concentration-time profiles of (+)-JQ1 after oral dosing (10 mg/kg). The pharmacokinetic parameters for oral (+)-JQ1 demonstrate excellent oral bioavailability (F=49%), peak plasma concentration (Cmax=1180 ng/mL) and drug exposure (AUC=2090 hr*ng/mL).
特別提示:本公司的所有產(chǎn)品僅可用于科研實(shí)驗(yàn),嚴(yán)禁用于臨床醫(yī)療及其他非科研用途!
關(guān)鍵字: (+)-JQ-1;(+)-JQ-1
上海澤葉生物科技有限公司是一家服務(wù)于生命科學(xué)領(lǐng)域的高新技術(shù)企業(yè),主要為科研機(jī)構(gòu)、高校、院所及企業(yè)產(chǎn)品開(kāi)發(fā)研究提供所需要的科研類試劑、耗材、儀器、技術(shù)服務(wù)等。包括分子生物學(xué)、免疫學(xué)、微生物學(xué)、細(xì)胞學(xué)、材料科學(xué),通用試劑、藥物合成試劑、手性化合物、催化劑及配體、分析試劑、生物試劑,檢測(cè)試劑等等